Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

By R. Perez-soler, A. Chachoua, L. Hammond, E. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. Clark, P. Santabarbara, P. Bonomi. Journal of Clinical Oncology, 2004

1,103 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f195651181beab1afa2018a65f99a1b7f85d7fae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Engelman
2. K. Imai
3. A. Takaoka
4. P. Jänne

In Pulmonary and Respiratory Medicine

1. J. Engelman
2. B. Hughes
3. B. Chan
4. K. Imai
5. A. Takaoka
6. P. Jänne

Citations in the corpus

• Comparing antibody and small-molecule therapies for cancer (2006, background): “In a series of clinical trials, gefitinib and erlotinib caused objective responses in 10–20% of previously treated patients with NSCL”
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors (2009, neutral): “Treatment with the reversible EGFR TK inhibitors (TKIs), gefitinib and erlotinib, results in dramatic antitumor activity in a subset of patients with NSCLC: clinical responses have been achieved in approximately 10% of European patients and in 30% of patients from East Asia (Fukuoka et al., 2003; Kr”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, methodology): “Early trials used EGFR TKIs in an unselected population as these predated the now known clinical and molecular predictive biomarkers (24-28).”
• Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. (2005, background): “First, similar cutaneous effects develop regardless of the mechanism of action of the EGFR inhibitor as a monoclonal antibody (cetuximab, panitumumab, matuzumab) [2‐5, 17] or as an EGFR-specific tyrosine kinase inhibitor (gefitinib, erlotinib) [12, 14, 15, 18 ].”
• Erlotinib in lung cancer - molecular and clinical predictors of outcome. (2005, background): “Low trisomy (3 gene copies in 10–39% of cells) 23 (18)”